News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
677,934 Results
Type
Article (38779)
Company Profile (253)
Press Release (638902)
Section
Business (203540)
Career Advice (1978)
Deals (35369)
Drug Delivery (77)
Drug Development (80616)
Employer Resources (167)
FDA (15981)
Job Trends (14788)
News (343675)
Policy (32423)
Tag
Academia (2529)
Africa (710)
Alliances (48992)
Alzheimer's disease (1132)
Approvals (15927)
Arizona (169)
Artificial intelligence (64)
Asia (36774)
Australia (5989)
Bankruptcy (350)
Best Places to Work (11218)
Biosimilars (60)
Biotechnology (177)
C2C Services and Suppliers (78813)
California (1524)
Canada (829)
Cancer (320)
Career advice (1646)
Cell therapy (96)
China (109)
Clinical research (62947)
Collaboration (105)
Colorado (64)
Connecticut (59)
COVID-19 (2477)
Cystic fibrosis (71)
Data (124)
Diabetes (64)
Diagnostics (5943)
Drug pricing (59)
Earnings (83632)
Employer resources (140)
Europe (78515)
Events (107443)
Executive appointments (86)
FDA (16145)
Florida (207)
Funding (91)
Gene therapy (74)
GLP-1 (497)
Government (4282)
Healthcare (18585)
Hotbed/Location (481303)
Idaho (56)
Illinois (230)
Indiana (133)
Infectious disease (2501)
Inflammatory bowel disease (87)
Interviews (306)
IPO (16173)
Job creations (3627)
Job search strategy (1413)
Kansas (93)
Layoffs (388)
Legal (7829)
Lung cancer (69)
Manufacturing (71)
Maryland (338)
Massachusetts (1272)
Medical device (13014)
Medtech (13017)
Mergers & acquisitions (19000)
Metabolic disorders (213)
Michigan (114)
Minnesota (203)
Neuroscience (1241)
New Jersey (468)
New York (476)
NextGen Class of 2024 (6488)
Non-profit (4453)
North Carolina (557)
Northern California (693)
Obesity (132)
Ohio (96)
Opinion (167)
Patents (55)
Pennsylvania (512)
People (55757)
Pharmaceutical (59)
Phase I (19507)
Phase II (27730)
Phase III (20714)
Pipeline (91)
Postmarket research (2546)
Preclinical (8303)
Press Release (64)
Rare diseases (111)
Real estate (5891)
Recruiting (63)
Regulatory (21147)
Research institute (2301)
Resumes & cover letters (346)
South America (1084)
Southern California (624)
Startups (3561)
Texas (179)
United States (7274)
Vaccines (443)
Washington State (233)
Weight loss (116)
Date
Last 7 days (461)
Last 30 days (2177)
Last 365 days (37439)
2024 (24458)
2023 (40103)
2022 (51230)
2021 (55765)
2020 (54127)
2019 (46569)
2018 (35043)
2017 (32146)
2016 (31522)
2015 (37590)
2014 (31361)
2013 (26383)
2012 (28585)
2011 (29284)
2010 (27353)
677,934 Results for "atara biotherapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 07, 2024
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 9,700 restricted stock units of Atara’s common stock to one newly hired employee.
June 7, 2024
·
2 min read
Deals
Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
Atara Biotherapeutics, Inc. today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25 (the “Reverse Stock Split”).
June 17, 2024
·
5 min read
Biotech Beach
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 03, 2024
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 4,150 restricted stock units of Atara’s common stock to one newly hired employee.
May 3, 2024
·
2 min read
Biotech Beach
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 05, 2024
Atara Biotherapeutics, Inc. reported the grant of 3,750 restricted stock units of Atara’s common stock to one newly hired employee.
April 5, 2024
·
2 min read
Biotech Bay
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that EbvalloTM (tabelecleucel or tab-cel®) has been awarded the prestigious 2024 Prix Galien International Award for “Best Product for Orphan/Rare Diseases.”
June 21, 2024
·
5 min read
Biotech Bay
Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced that Pascal Touchon, President and Chief Executive Officer and Cokey Nguyen, Ph.D., Executive Vice President, Chief Scientific & Technical Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024 at 6:20 a.m. PDT / 9:20 a.m. EDT.
June 5, 2024
·
1 min read
Business
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024.
May 9, 2024
·
17 min read
Business
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today reported financial results for the fourth quarter and full year 2023, recent business highlights, and key upcoming milestones for 2024.
March 28, 2024
·
16 min read
Drug Development
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced preclinical data supporting the potential of ATA3219, an allogeneic, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy candidate for the treatment of B-cell driven autoimmune diseases.
May 29, 2024
·
8 min read
Biotech Beach
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel ® ) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA .
May 20, 2024
·
6 min read
1 of 67,794
Next